Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Capital Expenditures (2016 - 2025)

KalVista Pharmaceuticals' Capital Expenditures history spans 10 years, with the latest figure at $342000.0 for Q2 2025.

  • For Q2 2025, Capital Expenditures fell 8.56% year-over-year to $342000.0; the TTM value through Apr 2025 reached $845000.0, up 110.72%, while the annual FY2025 figure was $495000.0, 23.44% up from the prior year.
  • Capital Expenditures for Q2 2025 was $342000.0 at KalVista Pharmaceuticals, up from $108000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $374000.0 in Q2 2024 and bottomed at $2000.0 in Q4 2023.
  • The 3-year median for Capital Expenditures is $21000.0 (2024), against an average of $124571.4.
  • The largest annual shift saw Capital Expenditures surged 5300.0% in 2024 before it dropped 8.56% in 2025.
  • A 3-year view of Capital Expenditures shows it stood at $2000.0 in 2023, then soared by 5300.0% to $108000.0 in 2024, then surged by 216.67% to $342000.0 in 2025.
  • Per Business Quant, the three most recent readings for KALV's Capital Expenditures are $342000.0 (Q2 2025), $108000.0 (Q4 2024), and $21000.0 (Q3 2024).